PORTFOLIO CMC ADVISORS
Most Phase 2 manufacturing failures weren't created in Phase 2.
They were already present — quietly —…
THE PROBLEM
The gap you can't see is the one that scales.
Biotech programs are financed and managed around visible clinical progress. Manufacturing understanding matures more slowly and far less visibly — so for a stretch of development, enterprise exposure and process understanding drift apart without anyone deciding to let them.
Early success makes it worse, not better: repeated batch success gets read as proof of readiness, when what it usually proves is feasibility inside a narrow operating window. The window holds — right up until scale, tech transfer, and distributed execution test its edges all at once, at exactly the moment the most is riding on the program. The failure looks sudden. It almost never is.
THE FRAMEWORK
A framework for seeing it earlier.
The Phase 2 Manufacturing Wall™ is a framework for understanding how hidden manufacturing fragility becomes enterprise risk as programs scale — why organizations miss the warning signs, and where the earlier intervention window actually sits. It's written for the people who carry that exposure: executive teams, investors, boards, and the CMC leaders who see the fragility first. Co-authored with Bharat Gurale, Ph.D.
Read the white paper →
THE DIAGNOSTIC
Locate your own program.
The Readiness–Exposure Gap™ is a short self-assessment that places your program on the same curve the framework describes — scoring how deeply the process is understood against how much the enterprise now depends on it.
It doesn't grade you, and it won't tell you you're failing. It shows you where exposure may be outrunning understanding, while looking is still inexpensive.
Take the diagnostic →
WHO'S BEHIND THIS
Lonnie Robarge, Ph.D.
I've spent 25+ years in small-molecule CMC and process development, operating where manufacturing, development, and business strategy meet — long enough to watch the same pattern repeat across very different companies. A program advances cleanly, the clean run gets read as readiness, and the manufacturing fragility that was there the whole time only surfaces once the enterprise has scaled around the assumption that it wasn't. I've been in the room for the good version of this — three FDA approvals, registration-scale supply, an 85% reduction in cost of goods — and for the hard version, where the gap surfaces late and expensive. The Phase 2 Manufacturing Wall is my attempt to name that pattern precisely enough that it can be seen, and acted on, before the cost compounds.
Through Portfolio CMC Advisors, I work with executive teams, investors, and boards on manufacturing-readiness reviews, fractional CMC leadership, board- and investor-level diligence, and CDMO network strategy — usually at the moments when exposure is about to step up: a financing event, a tech transfer, a scale-up.
25+ yrs
Small-molecule CMC & process development
3
FDA approvals supported
85%
Reduction in cost of goods delivered
4
Advisory engagement types, exec to board
If your program is approaching a financing event, a tech transfer, or a scale-up — and you want a clear-eyed read on the manufacturing exposure underneath it — let's talk.
PORTFOLIO CMC ADVISORS
lrobarge@portfoliocmc.com
© 2026 Lonnie Robarge. The Phase 2 Manufacturing Wall™ and the Readiness–Exposure Gap™ are trademarks of Portfolio CMC Advisors. All rights reserved.